UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Pharmacodynamics of fluoroquinolones against Streptococcus pneumoniae in patients with community-acquired respiratory tract infections

Antimicrobial agents and chemotherapy, 2001-10, Vol.45 (10), p.2793-2797

2001

Volltextzugriff (PDF)

Pharmacodynamics, Safety, and Pharmacokinetics of BMS-663068, an Oral HIV-1 Attachment Inhibitor in HIV-1-Infected Subjects

The Journal of infectious diseases, 2012-10, Vol.206 (7), p.1002-1011

2012

Volltextzugriff (PDF)

Pharmacometrics and the Transition to Model-Based Development

Clinical pharmacology and therapeutics, 2007-08, Vol.82 (2), p.137-142

2007

Volltextzugriff (PDF)

Multiple-Dose Safety and Pharmacokinetics of Oral Garenoxacin in Healthy Subjects

Antimicrobial Agents and Chemotherapy, 2003-07, Vol.47 (7), p.2256-2263

2003

Volltextzugriff (PDF)

Clinical Pharmacology of Gatifloxacin, a New Fluoroquinolone

Clinical infectious diseases, 2000-08, Vol.31 (Supplement-2), p.S51-S58

GRASELA, Dennis M

2000

Volltextzugriff (PDF)

PO.6.132 A phase 2b study of afimetoran (BMS-986256) in patients with active systemic lupus erythematosus (SLE): optimization of a lupus clinical trial design

Lupus science & medicine, 2022-10, Vol.9 (Suppl 2), p.A100-A101

2022

Volltextzugriff (PDF)

The effects of HIV protease inhibitors atazanavir and lopinavir/ritonavir on insulin sensitivity in HIV-seronegative healthy adults

AIDS (London), 2004-11, Vol.18 (16), p.2137-2144

2004

Volltextzugriff (PDF)

P1162 EFFECT OF RIBAVIRIN ON THE SAFETY PROFILE OF DACLATASVIR + SOFOSBUVIR FOR PATIENTS WITH CHRONIC HCV INFECTION

Journal of hepatology, 2014-04, Vol.60 (1), p.S471-S471

2014

Volltextzugriff (PDF)

The use of Monte Carlo simulation to examine pharmacodynamic variance of drugs: fluoroquinolone pharmacodynamics against Streptococcus pneumoniae

Diagnostic microbiology and infectious disease, 2000-11, Vol.38 (3), p.151-157

2000

Volltextzugriff (PDF)

Randomized, placebo-controlled single-ascending-dose study to evaluate the safety, tolerability and pharmacokinetics of the HIV nucleoside reverse transcriptase inhibitor, BMS-986001, in healthy subjects

Journal of clinical pharmacology, 2014-06, Vol.54 (6), p.657-664

2014

Volltextzugriff (PDF)

P1163 ALL-ORAL THERAPY WITH DACLATASVIR IN COMBINATION WITH ASUNAPREVIR AND BMS-791325 FOR TREATMENT-NAIVE PATIENTS WITH CHRONIC HCV GENOTYPE 4 INFECTION

Journal of hepatology, 2014-04, Vol.60 (1), p.S472-S472

2014

Volltextzugriff (PDF)

1422 POTENT VIRAL SUPPRESSION WITH ALL-ORAL COMBINATION OF DACLATASVIR (NS5A INHIBITOR) AND GS-7977 (NS5B INHIBITOR), +/− RIBAVIRIN, IN TREATMENT-NAIVE PATIENTS WITH CHRONIC HCV GT1, 2, OR 3

Journal of hepatology, 2012-04, Vol.56, p.S560-S560

2012

Volltextzugriff (PDF)

1415 CONFIRMATION THAT QUADRUPLE THERAPY WITH DACLATASVIR (NS5A INHIBITOR), ASUNAPREVIR (NS3 INHIBITOR) AND PEGINTERFERON/RIBAVIRIN RESULTS IN HIGH RATE OF SVR4 IN HCV GENOTYPE 1 NULL RESPONDERS

Journal of hepatology, 2012-04, Vol.56, p.S557-S557

2012

Volltextzugriff (PDF)

POS0672 ASSESSMENT OF THE DRUG-DRUG INTERACTION POTENTIAL OF BRANEBRUTINIB (BMS-986195), A HIGHLY POTENT AND SELECTIVE IRREVERSIBLE COVALENT INHIBITOR OF BRUTON’S TYROSINE KINASE, IN HEALTHY PARTICIPANTS

Annals of the rheumatic diseases, 2022-06, Vol.81 (Suppl 1), p.610-610

2022

Volltextzugriff (PDF)

1356 QUADRUPLE THERAPY WITH BMS-790052, BMS-650032 AND PEG-IFN/RBV FOR 24 WEEKS RESULTS IN 100% SVR12 IN HCV GENOTYPE 1 NULL RESPONDERS

Journal of hepatology, 2011-03, Vol.54, p.S536-S536

2011

Volltextzugriff (PDF)

A Dose-Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Intravenous Gatifloxacin in Healthy Adult Men

Pharmacotherapy, 2000-06, Vol.20 (6P2), p.49S-58S

2000

Volltextzugriff (PDF)

Effect of Multiple-Dose Gatifloxacin or Ciprofloxacin on Glucose Homeostasis and Insulin Production in Patients with Noninsulin-Dependent Diabetes Mellitus Maintained with Diet and Exercise

Pharmacotherapy, 2000-06, Vol.20 (6P2), p.76S-86S

2000

Volltextzugriff (PDF)

Ecological impact of the des-F(6)-quinolone, BMS-284756, on the normal intestinal microflora

Clinical microbiology and infection, 2002-04, Vol.8 (4), p.229-239

2002

Volltextzugriff (PDF)

Pharmacokinetics of Single-Dose Oral Stavudine in Subjects with Renal Impairment and in Subjects Requiring Hemodialysis

Antimicrobial Agents and Chemotherapy, 2000-08, Vol.44 (8), p.2149-2153

2000

Volltextzugriff (PDF)

Interchangeability of 400-mg Intravenous and Oral Gatifloxacin in Healthy Adults

Pharmacotherapy, 2000-06, Vol.20 (6P2), p.59S-66S

2000

Volltextzugriff (PDF)

Pharmacokinetics and safety of a single dose of stavudine (d4T) in patients with severe hepatic impairment

Antimicrobial Agents and Chemotherapy, 1997-12, Vol.41 (12), p.2793-2796

1997

Volltextzugriff (PDF)

Age and Gender Effects on the Pharmacokinetics of Gatifloxacin

Pharmacotherapy, 2000-06, Vol.20 (6P2), p.67S-75S

2000

Volltextzugriff (PDF)

Open-Label, Nonrandomized Study of the Effects of Gatifloxacin on the Pharmacokinetics of Midazolam in Healthy Male Volunteers

Pharmacotherapy, 2000-03, Vol.20 (3), p.330-335

2000

Volltextzugriff (PDF)

Effect of Garenoxacin on Eubacteria in the Normal Intestinal Microflora when Administered Concomitantly with Digoxin

Journal of chemotherapy (Florence), 2003, Vol.15 (3), p.244-247

2003

Volltextzugriff (PDF)

Safety and Pharmacokinetics of a Single Oral Dose of Gatifloxacin in Patients with Moderate to Severe Hepatic Impairment

Pharmacotherapy, 2000-06, Vol.20 (6P2), p.87S-94S

2000

Volltextzugriff (PDF)

1 – 25 von 116

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(109)
Mit Volltextzugriff
(79)

Publikationsform

Artikel
(116)

Sprache

Englisch
(116)

Erscheinungsjahr

n.n

Thema

Humans
(78)
Science & Technology
(76)
Life Sciences & Biomedicine
(74)
Biological And Medical Sciences
(51)
Medical Sciences
(51)
Male
(50)
Pharmacology & Pharmacy
(48)
Pharmacology. Drug Treatments
(46)
Female
(44)
Adult
(42)
Middle Aged
(36)
Antibiotics. Antiinfectious Agents. Antiparasitic Agents
(26)
Aged
(22)
Adolescent
(17)
Fluoroquinolones
(16)
Microbiology
(16)
Antibacterial Agents
(15)
Pharmacokinetics
(15)
Administration, Oral
(14)
Anti-Infective Agents - Administration & Dosage
(11)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Pharmacodynamics of fluoroquinolones against Streptococcus pneumoniae in patients with community-acquired respiratory tract infections

Pharmacodynamics, Safety, and Pharmacokinetics of BMS-663068, an Oral HIV-1 Attachment Inhibitor in HIV-1-Infected Subjects

Pharmacometrics and the Transition to Model-Based Development

Multiple-Dose Safety and Pharmacokinetics of Oral Garenoxacin in Healthy Subjects

Clinical Pharmacology of Gatifloxacin, a New Fluoroquinolone

PO.6.132 A phase 2b study of afimetoran (BMS-986256) in patients with active systemic lupus erythematosus (SLE): optimization of a lupus clinical trial design

The effects of HIV protease inhibitors atazanavir and lopinavir/ritonavir on insulin sensitivity in HIV-seronegative healthy adults

P1162 EFFECT OF RIBAVIRIN ON THE SAFETY PROFILE OF DACLATASVIR + SOFOSBUVIR FOR PATIENTS WITH CHRONIC HCV INFECTION

The use of Monte Carlo simulation to examine pharmacodynamic variance of drugs: fluoroquinolone pharmacodynamics against Streptococcus pneumoniae

Randomized, placebo-controlled single-ascending-dose study to evaluate the safety, tolerability and pharmacokinetics of the HIV nucleoside reverse transcriptase inhibitor, BMS-986001, in healthy subjects

P1163 ALL-ORAL THERAPY WITH DACLATASVIR IN COMBINATION WITH ASUNAPREVIR AND BMS-791325 FOR TREATMENT-NAIVE PATIENTS WITH CHRONIC HCV GENOTYPE 4 INFECTION

1422 POTENT VIRAL SUPPRESSION WITH ALL-ORAL COMBINATION OF DACLATASVIR (NS5A INHIBITOR) AND GS-7977 (NS5B INHIBITOR), +/− RIBAVIRIN, IN TREATMENT-NAIVE PATIENTS WITH CHRONIC HCV GT1, 2, OR 3

1415 CONFIRMATION THAT QUADRUPLE THERAPY WITH DACLATASVIR (NS5A INHIBITOR), ASUNAPREVIR (NS3 INHIBITOR) AND PEGINTERFERON/RIBAVIRIN RESULTS IN HIGH RATE OF SVR4 IN HCV GENOTYPE 1 NULL RESPONDERS

POS0672 ASSESSMENT OF THE DRUG-DRUG INTERACTION POTENTIAL OF BRANEBRUTINIB (BMS-986195), A HIGHLY POTENT AND SELECTIVE IRREVERSIBLE COVALENT INHIBITOR OF BRUTON’S TYROSINE KINASE, IN HEALTHY PARTICIPANTS

1356 QUADRUPLE THERAPY WITH BMS-790052, BMS-650032 AND PEG-IFN/RBV FOR 24 WEEKS RESULTS IN 100% SVR12 IN HCV GENOTYPE 1 NULL RESPONDERS

A Dose-Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Intravenous Gatifloxacin in Healthy Adult Men

Effect of Multiple-Dose Gatifloxacin or Ciprofloxacin on Glucose Homeostasis and Insulin Production in Patients with Noninsulin-Dependent Diabetes Mellitus Maintained with Diet and Exercise

Ecological impact of the des-F(6)-quinolone, BMS-284756, on the normal intestinal microflora

Pharmacokinetics of Single-Dose Oral Stavudine in Subjects with Renal Impairment and in Subjects Requiring Hemodialysis

Interchangeability of 400-mg Intravenous and Oral Gatifloxacin in Healthy Adults

Pharmacokinetics and safety of a single dose of stavudine (d4T) in patients with severe hepatic impairment

Age and Gender Effects on the Pharmacokinetics of Gatifloxacin

Open-Label, Nonrandomized Study of the Effects of Gatifloxacin on the Pharmacokinetics of Midazolam in Healthy Male Volunteers

Effect of Garenoxacin on Eubacteria in the Normal Intestinal Microflora when Administered Concomitantly with Digoxin

Safety and Pharmacokinetics of a Single Oral Dose of Gatifloxacin in Patients with Moderate to Severe Hepatic Impairment

Suchergebnisse filtern